Classes
- Student Research ActivityC3SVA0061 | Third Faculty of Medicine
- Summer Practice in Compulsory FieldC5VL017 | Third Faculty of Medicine
- ?CCOC5938 | Third Faculty of Medicine
- . +1CCOC5938L | Third Faculty of Medicine
- Autoimune endocrinopathiesCCOC6922 | Third Faculty of Medicine
- Clinical Manifestation of Immune DisordersCCOC71S | Third Faculty of Medicine
- Malignancies of B and T lymphocytes +6CCOC8959 | Third Faculty of Medicine
- Basic skills in Emergency medical service +1CCOCA0004 | Third Faculty of Medicine
- Basic skill of physician in emergency dutiesCCOCA0023 | Third Faculty of Medicine
- Principles of Evidence-based Medicine and Basic research TrainingCCVOL25 | Third Faculty of Medicine
Publications
- HLA DRB1, DQB1 and insulin promoter VNTR polymorphisms: interactions and the association with adult-onset diabetes mellitus in Czech patients2008 | Third Faculty of Medicine
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Hematologie v kostce +12023 | Central Library of Charles University, Third Faculty of Medicine
- Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab2023 | Third Faculty of Medicine
- Immune thrombocytopenia in a patient with essential thrombocythemia after SARS-CoV-2 infection: A case report2023 | Third Faculty of Medicine
- High pre-transplant Mucosal Associated Invariant T Cell (MAIT) count predicts favorable course of myeloid aplasia2023 | Third Faculty of Medicine
- Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial2023 | Third Faculty of Medicine
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial2022 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey2022 | Central Library of Charles University, Third Faculty of Medicine
- Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study2022 | Third Faculty of Medicine
Loading network view...